Testosterone treatment comes of age: new options for hypogonadal men
- 18 July 2006
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 65 (3), 275-281
- https://doi.org/10.1111/j.1365-2265.2006.02618.x
Abstract
Male hypogonadism is one of the most frequent, but also most underdiagnosed, endocrinopathies. However, the required testosterone treatment is simple and very effective if properly administered. Although testosterone has been available for clinical use for seven decades, until quite recently the treatment modalities were far from ideal. Subdermal testosterone pellets require minor surgery for insertion and often cause local problems. The injectable testosterone enanthate, for a long period the most frequently used mode of administration, lasts for two to four weeks, but produces supraphysiological levels initially and low levels before the next injection. The oral testosterone undecanoate has to be taken three times daily, has an uncertain absorption pattern and results in peaks and valleys of serum testosterone levels throughout the day. With the advent of transdermal testosterone preparations, the desired physiological serum levels could be achieved for the first time. Scrotal testosterone patches were the first to fulfil this requirement. These were followed by nonscrotal skin patches, which, however, cause considerable skin reactions including erythema and blisters. Recently introduced, invisible transdermal testosterone gels increased the intervals of application and are now slowly replacing other modalities. A mucoadhesive buccal testosterone tablet with sustained release is also a recent competing modality. Finally, injectable testosterone undecanoate in castor oil was made into a real depot preparation requiring only four injections per year for replacement therapy. These new preparations with a desired pharmacokinetic testosterone profile give the patient a real choice and make treatment easier. Based on pharmacogenetic considerations taking the androgen receptor polymorphism into account, treatment may be individualized for each patient in the future.Keywords
This publication has 78 references indexed in Scilit:
- Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingNature Clinical Practice Endocrinology & Metabolism, 2006
- Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendationsInternational Journal of Andrology, 2005
- Abuse of androgens and detection of illegal usePublished by Cambridge University Press (CUP) ,2001
- Hormonal male contraception: the essential role of testosteronePublished by Cambridge University Press (CUP) ,2001
- Selective androgen receptor modulators (SARMs)Published by Cambridge University Press (CUP) ,2001
- Pharmacology of testosterone preparationsPublished by Cambridge University Press (CUP) ,2001
- Clinical uses of testosterone in hypogonadism and other conditionsPublished by Cambridge University Press (CUP) ,2001
- Testosterone effects on the skeletal musclePublished by Cambridge University Press (CUP) ,2001
- Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal menClinical Endocrinology, 1996
- ANDROGENSObstetrical & Gynecological Survey, 1956